Researchers found significant sex-based differences in ILD in patients with interdisciplinary indications for complete ...

Topline data from FIBRONEER-ILD showed that nerandomilast met its ... held German pharma group's human pharma division. In IPF and PPF, the lungs become increasingly damaged by scar tissue ...

The FIBRONEER-ILD results come five months after a separate ... Ofev’s competitor on the IPF and PPF market, Roche’s Esbiret (pirfenidone), saw its sales drop dramatically in 2023, making ...

There are over 100 types of interstitial lung disease. Age, genetics, smoking, and medical treatments can all predispose a ...

There are about 200 different conditions that are categorized under ILD. The conditions commonly considered as ILDs include various disorders such as idiopathic pulmonary fibrosis (IPF), connective ...

With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy Ofev.

In addition to patients with IPF and progressive pulmonary fibrosis ("PPF"), patients suffering from ... NXP002 has been studied in tissue from an autoimmune ILD explanted lung (in this case ...

This study has been published. Description of Palliative Care Models in ILD Clinics and their impact on IPF care* A multi-centre retrospective study comparing novel palliative care models and their ...

Dr Ahmed Fahim discusses the UK Idiopathic Pulmonary Fibrosis Registry and how its findings enhance understanding and clinical management.

may be contributing to risks for rheumatoid arthritis and RA-associated interstitial lung disease, according to findings published in Arthritis & Rheumatology. Jobs with high IPF mortality ratios ...